The University of Kansas Cancer Center-Westwood
Westwood, Kansas 66205
7 studies enrolling now · 12 studies all time
What they study most
Biliary Tract Cancer, Breast Neoplasms, CRC, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Cutaneous Squamous Cell Cancer, ET-MF, Endometrial, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Exocrine Pancreatic Adenocarcinoma
Studies at this site
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer — Recruiting now
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting now
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer — Recruiting now
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
- Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
- A Study of SGN-MesoC2 in Advanced Solid Tumors — Stopped early
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Running, not enrolling
- Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells — Enrolling by invitation
- Study of Canakinumab in Patients With Myelofibrosis — Running, not enrolling
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias — Starting soon